This week on Surfing NASH, co-hosts Jörn Schattenberg and Roger Green review the recently concluded Liver Forum. Joining discussion are Liver Forum Executive Director Veronica Miller and speakers Mazen Noureddin (Houston Research Institute), Michelle Long (Novo Nordisk) and Jeff McIntyre (Global Liver Institute).
Roger leads this conversation by asking the panelists to pick a particular session that captured their attention in a way that could not have been predicted. Michelle first mentions how the agenda as a whole illuminated the depth of the issues surrounding drug development for the fatty liver field. Veronica points to an interactive session titled NASH Drug Development in the Era of Approved Drugs, commending friends of the podcast Manal Abdelmalek and Pamela Danagher for their brilliant moderation. She says that hosting an unscripted panel in a safe environment with engaged participants is a way to “push the envelope and move the field forward.” Jörn notes data presented from the European Heart Journal as an exciting example of exploring and utilizing literature from outside the liver field. At this point, Mazen offers a more tangible description of some content covered. He details general concepts behind a session on Cirrhosis Working Group Updates which included his presentation on Compensated Cirrhosis Risk Stratification. As the conversation winds down, Veronica reminds that the slides from the event are published on the Liver Forum website and well worth a review.
If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!